sponsored
PatientsVille.com Logo

PatientsVille

Trimethoprim Medical Research Studies

Up-to-date List of Trimethoprim Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Trimethoprim Medical Research Studies

Rank Status Study
1 Recruiting Study of Trimethoprim/Sulfamethoxazole as PCP Prophylaxis in CTD Patients
Conditions: Pneumonia, Pneumocystis;   Prevention & Control
Intervention: Drug: Trimethoprim/Sulfamethoxazole
Outcome Measures: Documented PCP infection;   PCP-related mortality;   All cause mortality;   Other infections;   PCP-related hospitalization
2 Unknown  Influence of Trimethoprim-Sulfamethoxazole for the Recurrence of Ocular Toxoplasmosis
Condition: Ocular Toxoplasmosis
Intervention: Drug: Trimethoprim-Sulfamethoxazole
Outcome Measure: Incidence of episodes of recurrent chorioretinitis by toxoplasmosis in the follow up of 12 months.
3 Unknown  Antibiotics Versus Placebo in the Treatment of Abscesses in the Emergency Department
Condition: Abscess
Interventions: Drug: Trimethoprim-sulfamethoxazole;   Drug: Sugar pill
Outcome Measures: The objective of this study is to compare clinical indicators of abscess resolution for two different treatment methods: 1) incision and drainage plus placebo (I&D/P) and 2) incision and drainage plus Trimethoprim-sulfamethoxazole (TMP-SMX) (I&D/T-S).;   Comparison of medication adverse effect profiles between the groups, comparison of outcomes between MRSA isolates versus other pathogens between the groups, and analysis of interrater reliability of physical exam findings for a subgroup of patients.
4 Recruiting Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on ART in Blantyre, Malawi
Condition: HIV
Interventions: Drug: Standard of Care prophylaxis;   Drug: Chloroquine (CQ) prophylaxis
Outcome Measures: Severe events;   HIV viral load;   CD4 cell count;   WHO HIV stage 2, 3, 4 illness;   Bacterial infections and malaria;   Adverse events greater than or equal to Grade 3 that are related to the study product
5 Recruiting A Pharmacokinetic and Pharmacogenetic Study in Patients Receiving Sulfamethoxazole-Trimethoprim Therapy
Condition: Pneumocystis Jiroveci Pneumonia
Intervention:
Outcome Measure: High performance liquid chromatography for drug plasma concentration
6 Recruiting Randomized Clinical Trial to Compare a Regimen of Trimethoprim-sulfamethoxazole Plus Rifampicin With a Regimen of Linezolid in the Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection
Condition: MRSA Infection
Interventions: Drug: Trimethoprim-sulfamethoxazole (TMP-SMX);   Drug: Linezolid;   Drug: Rifampicin
Outcome Measures: Bacteriological and clinical cure;   Treatment costs
7 Recruiting Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Condition: Staphylococcal Infection
Interventions: Drug: Clindamycin;   Drug: Trimethoprim-sulfamethoxazole (TS);   Drug: Placebo
Outcome Measures: Clinical cure, defined as absence of clinical failure.;   Efficacy outcome: clinical cure of recurrences or relapses of SSTI.;   Safety outcomes: adverse events; and adverse events that are treatment limiting.
8 Recruiting The SCOUT Study: Short Course Therapy for Urinary Tract Infections in Children
Condition: Urinary Tract Infections
Interventions: Drug: Trimethoprim sulfamethoxazole, amoxicillin-clavulanate, cefixime, or cephalexin;   Drug: Placebo
Outcome Measures: Occurrence of treatment failures between short-course and standard-course therapies;   Occurrence of recurrent infections;   Occurrence of colonization with antimicrobial resistant bacteria;   Occurrence of asymptomatic bacteriuria;   Occurrence of clinical symptoms;   Occurrence of positive urine cultures
9 Recruiting Efficacy of Fosfomycin-Trometamol in Urinary Tract Infection Prophylaxis After Kidney Transplantation
Conditions: Urinary Tract Infection;   Asymptomatic Bacteriuria;   Allograft Rejection;   Microbiologic Resistance;   Hospitalization
Interventions: Drug: Fosfomycin-Trometamol;   Drug: Sulfamethoxazole Trimethoprim
Outcome Measures: Urinary tract infection incidence in the first six months after kidney transplantation;   Complications related to the intervention, including rate of microbiological resistance.
10 Recruiting Prophylactic Antibiotics or Placebo After Hypospadias Repair
Condition: Hypospadias
Interventions: Drug: Trimethoprim-sulfamethoxazole;   Other: placebo
Outcome Measures: postoperative infection;   wound-healing complications;   adverse drug reaction;   C. difficile colitis
11 Recruiting Antibiotic Prophylaxis in Children With Pyelonephritis
Condition: Pyelonephritis
Interventions: Drug: Trimethoprim Sulfamethoxazole;   Drug: placebo
Outcome Measures: To determine whether antibiotic prophylaxis prevents recurrent urinary tract infections by assessing if there is a decreased incidence of urinary tract infections.;   To determine whether antibiotic prophylaxis prevents long-term renal scarring by assessing results of DMSA scans to look at long term renal scarring.;   To determine whether recurrent infections and involvement with the medical system impacts quality of life by assessing how this medical condition affects children using standardized quality of life questionnaires.
12 Recruiting Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Cotrimoxazole;   Drug: Placebo
Outcome Measures: Evaluate the efficacy of oral cotrimoxazole versus placebo in idiopathic pulmonary fibrosis (IPF).;   Evaluate the safety of oral cotrimoxazole versus placebo in IPF.;   Evaluate the effect of cotrimoxazole on the natural history of Pneumocystis colonization in patients with IPF.;   Identify the effects of cotrimoxazole systemic level of inflammatory activity in patients with IPF.
13 Recruiting Antibiotic Prophylaxis and Renal Damage In Congenital Abnormalities of the Kidney and Urinary Tract
Conditions: Vesicoureteral Reflux;   Renal Hypodysplasia, Nonsyndromic, 1;   Chronic Kidney Disease
Interventions: Drug: nitrofurantoin;   Other: No prophylaxis;   Drug: Amoxicillin-Potassium Clavulanate Combination;   Drug: Trimethoprim/sulfamethoxazole;   Drug: Cefixime
Outcome Measures: urinary tract infections rate;   febrile urinary tract infections;   renal scars;   serum creatinine (renal function);   hypertension;   proteinuria;   body mass index;   serum cystatin C (renal function)
14 Recruiting Antibiotic Prophylaxis for Clean Intermittent Catheterisation
Condition: Urinary Tract Infection: [Site Not Specified] or [Recurrent]
Interventions: Drug: Nitrofurantoin or Trimethoprim or Cefalexin;   Other: No prophylaxis
Outcome Measure: Relative incidence of symptomatic antibiotic‐treated UTI
15 Unknown  Efficacy of Surgical Treatment of Osteomyelitis in Diabetic Foot Ulcers
Conditions: Osteomyelitis;   Diabetic Foot;   Diabetic Foot Ulcers
Interventions: Procedure: Conservative surgery;   Drug: Ciprofloxacin;   Drug: Amoxicillin-Potassium Clavulanate Combination;   Drug: Sulfamethoxazole Trimethoprim
Outcome Measures: Number of healing patients;   Reulceration;   Healing time;   Complications;   Quality of life
16 Unknown  Randomized Controlled Trial of Antibiotics in the Management of Children With Community-Acquired Skin and Soft Tissue Abscess Undergoing Incision and Drainage
Conditions: Skin and Soft Tissue Abscess;   Methicillin-resistant Staphylococcus Aureus (MRSA) Infection
Intervention: Drug: Oral Clindamycin
Outcome Measures: The primary objective is to measure clinical resolution of skin abscess at routine follow-up visit 10-14 days post operation.;   Secondary outcomes measured include incidence of additional skin and soft tissue infections in patient and in household contacts as determined by healthcare provider. Compliance to antibiotic regime will also be assessed at this time.
17 Recruiting Compare Ceftazidime-Avibactam and Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)
Conditions: cUTI;   Complicated Urinary Tract Infection;   Acute Pyelonephritis
Interventions: Drug: CAZ-AVI;   Drug: Doripenem;   Drug: Either switch to oral therapy : 500 mg of Ciprofloxacin (oral);   Drug: or switch to oral therapy : 800 mg/160 mg of sulfamethoxazole/Trimethoprim
Outcome Measures: The proportion of patients with resolved (or return to premorbid) UTI (Urinary Tract Infection) symptoms except flank pain and resolution or improvement in flank pain based on patient-reported symptom assessment response;   The proportion of patients with a per patient microbiological eradication and resolution (or return to premorbid) of all UTI (Urinary Tract Infection)-specified symptoms based on patient-reported symptom assessment response;   The proportion of patients with a favorable per patient microbiological response in the microbiological modified Intent-To-Treat analysis set;   The proportion of patients with a favorable per patient microbiological response in the microbiologically evaluable analysis set;   The proportion of patients with a favorable per patient microbiological response in the extended microbiological evaluable analysis set;   The proportion of patients with resolution (or return to premorbid) of all UTI (Urinary Tract Infection)-specific symptoms based on the patient-reported symptom assessment response in the microbiological modified Intent-To-Treat analysis set;   The proportion of favorable per-pathogen microbiological response in the microbiological modified Intent-To-Treat analysis set;   The proportion of favorable per-pathogen microbiological response in the microbiologically evaluable analysis set;   The proportion of favorable per-pathogen microbiological response in the extended microbiologically evaluable analysis set;   The proportion of patients with an investigator-determined clinical cure in the microbiological modified Intent-To-Treat analysis set;   The proportion of patients with an investigator-determined clinical cure in the microbiologically evaluable analysis set;   The proportion of patients with an investigator-determined clinical cure in the extended microbiologically evaluable analysis set;   The proportion of patients with an investigator-determined clinical cure in the clinically evaluable analysis set;   The favorable per pathogen microbiologic response by categories of minimum inhibitory concentration in the microbiological modified Intent-To-Treat analysis set;   The favorable per pathogen microbiologic response by categories of minimum inhibitory concentration in the microbiologically evaluable analysis set;   The favorable per pathogen microbiologic response by categories of minimum inhibitory concentration in the extended microbiologically evaluable analysis set;   The proportion of patients with favorable investigator clinical response assessment in patients infected with a ceftazidime resistant pathogen in the microbiological modified Intent-To-Treat analysis set;   The proportion of patients with an investigator-determined clinical cure in patients infected with a ceftazidime resistant pathogen in the microbiologically evaluable analysis set;   The proportion of patients with an investigator-determined clinical cure in patients infected with a ceftazidime resistant pathogen in the extended microbiologically evaluable analysis set;   The proportion of patients with favorable per-patient microbiological response for patients infected with a ceftazidime resistant pathogen in the microbiological modified Intent-To-Treat analysis set;   The proportion of patients with favorable per-patient microbiological response for patients infected with a ceftazidime resistant pathogen in the microbiologically evaluable analysis set;   The proportion of patients with favorable per-patient microbiological response for patients infected with a ceftazidime resistant pathogen in the extended microbiologically evaluable analysis set;   The proportion of patients with symptomatic resolution (defined in the primary variables) for patients infected with a ceftazidime resistant pathogen in the microbiological modified Intent-To-Treat analysis set;   The time to first defervescence while on IV (intravenous) study therapy in patients in the microbiological modified Intent-To-Treat analysis set who have fever at study entry;   The time to first defervescence while on IV (intravenous) study therapy in patients in the microbiologically evaluable analysis set who have fever at study entry;   The time to first defervescence while on IV (intravenous) study therapy in patients in the extended microbiologically evaluable analysis set who have fever at study entry;   The time to first defervescence while on IV (intravenous) study therapy in patients in the clinically evaluable analysis set who have fever at study entry;   Profile of pharmacokinetic (PK) of the individual components of CAZ-AVI (avibactam and ceftazidime)- maximum plasma concentration (Cmax);   Profile of pharmacokinetic (PK) of the individual components of CAZ-AVI (avibactam and ceftazidime)- minimum plasma concentration (Cmin);   Profile of pharmacokinetic (PK) of the individual components of CAZ-AVI (avibactam and ceftazidime)- area under the plasma concentration time curve at steady state (AUCss);   Profile of pharmacokinetic (PK) of the individual components of CAZ-AVI (avibactam and ceftazidime)- terminal half-life (t½ );   The safety and tolerability profile by incidence and severity of adverse events and serious adverse events, vital signs, clinical laboratory tests, ECGs and physical exams
18 Recruiting Study to Improve Survival Among HIV-Exposed Infants in Botswana
Conditions: HIV Infections;   Neutropenia;   Anemia
Interventions: Drug: cotrimoxazole prophylaxis;   Drug: cotrimoxazole placebo;   Behavioral: exclusive breastfeeding until 6 months of age;   Behavioral: breastfeeding for 12 months
Outcome Measures: Survival;   HIV-free Survival;   Safety of CTX prophylaxis;   Morbidity and mortality
19 Recruiting Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)
Condition: Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Interventions: Drug: CAZ-AVI;   Drug: Doripenem;   Drug: Either switch to oral therapy: 500 mg of Ciprofloxacin (oral);   Drug: or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/Trimethoprim (oral)
Outcome Measures: The proportion of patients with resolved (or return to premorbid) UTI(Urinary Tract Infection)symptoms except flank pain and resolution or improvement in flank pain based on patient-reported symptom assessment response;   The proportion of patients with a per patient microbiological eradication and resolution (or return to premorbid) of all UTI-specified symptoms based on patient-reported symptom assessment response.;   The proportion of patients with a favorable per patient microbiological response in the microbiological modified Intent-To-Treat analysis set;   The proportion of patients with a favorable per patient microbiological response in the microbiologically evaluable analysis set.;   The proportion of patients with a favorable per patient microbiological response in the extended microbiological evaluable analysis set;   The proportion of patients with resolution (or return to premorbid) of all UTI-specific symptoms based on the patient-reported symptom assessment response in the microbiological modified Intent-To-Treat analysis set;   The proportion of favorable per-pathogen microbiological response in the microbiological modified Intent-To-Treat analysis set;   The proportion of favorable per-pathogen microbiological response in the microbiologically evaluable analysis set;   The proportion of favorable per-pathogen microbiological response in the extended microbiologically evaluable analysis set;   The proportion of patients with an investigator-determined clinical cure in the microbiological modified Intent-To-Treat analysis set;   The proportion of patients with an investigator-determined clinical cure in the microbiologically evaluable analysis set;   The proportion of patients with an investigator-determined clinical cure in the extended microbiologically evaluable analysis set;   The proportion of patients with an investigator-determined clinical cure in the clinically evaluable analysis set;   The favorable per pathogen microbiologic response by categories of minimum inhibitory concentration in the microbiological modified Intent-To-Treat analysis set;   The favorable per pathogen microbiologic response by categories of minimum inhibitory concentration in the microbiologically evaluable analysis set;   The favorable per pathogen microbiologic response by categories of minimum inhibitory concentration in the extended microbiologically evaluable analysis set;   The proportion of patients with favorable investigator clinical response assessment in patients infected with a ceftazidime resistant pathogen in the microbiological modified Intent-To-Treat analysis set;   The proportion of patients with an investigator-determined clinical cure in patients infected with a ceftazidime resistant pathogen in the microbiologically evaluable analysis set;   The proportion of patients with an investigator-determined clinical cure in patients infected with a ceftazidime resistant pathogen in the extended microbiologically evaluable analysis set;   The proportion of patients with favorable per-patient microbiological response for patients infected with a ceftazidime resistant pathogen in the microbiological modified Intent-To-Treat analysis set;   The proportion of patients with favorable per-patient microbiological response for patients infected with a ceftazidime resistant pathogen in the microbiologically evaluable analysis set;   The proportion of patients with favorable per-patient microbiological response for patients infected with a ceftazidime resistant pathogen in the extended microbiologically evaluable analysis set;   The proportion of patients with symptomatic resolution (defined in the co-primary variables) for patients infected with a ceftazidime resistant pathogen in the microbiological modified Intent-To-Treat analysis set;   The time to first defervescence while on IV (intravenous)study therapy in patients in the microbiological modified Intent-To-Treat analysis set who have fever at study entry;   The time to first defervescence while on IV (intravenous) study therapy in patients in the microbiologically evaluable analysis set who have fever at study entry;   The time to first defervescence while on IV (intravenous) study therapy in patients in the extended microbiologically evaluable analysis set who have fever at study entry;   The time to first defervescence while on IV (intravenous) study therapy in patients in the clinically evaluable analysis set who have fever at study entry;   Profile of pharmacokinetic (PK) of the individual components of CAZ-AVI (avibactam and ceftazidime)- maximum plasma concentration (Cmax);   Profile of pharmacokinetic (PK) of the individual components of CAZ-AVI (avibactam and ceftazidime)- minimum plasma concentration (Cmin);   Profile of pharmacokinetic (PK) of the individual components of CAZ-AVI (avibactam and ceftazidime)- area under the plasma concentration time curve at steady state (AUCss);   Profile of pharmacokinetic (PK) of the individual components of CAZ-AVI (avibactam and ceftazidime)- terminal half-life (t½ );   The safety and tolerability profile by incidence and severity of adverse events and serious adverse events, vital signs, clinical laboratory tests, ECGs and physical exams
20 Recruiting Effectiveness of Antibiotics Versus Placebo to Treat Antenatal Hydronephrosis
Conditions: Hydronephrosis;   Urinary Tract Infection
Interventions: Drug: Trimethoprim;   Other: Simple Syrup
Outcome Measure: To determine whether antibiotics (ATB) prophylaxis prevents urinary tract infection (UTI) in infants with antenatal hydronephrosis (AHN).

These studies may lead to new treatments and are adding insight into Trimethoprim etiology and treatment.

A major focus of Trimethoprim research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Trimethoprim